A recent report by the international market research firm YH Research, titled "Global Boron Neutron Capture Therapy (BNCT) Top Companies Market Share and Ranking 2026," highlights the rapid expansion of the global BNCT market. It is projected to grow from approximately $528 million in 2026 to about $3.39 billion by 2032, achieving a compound annual growth rate (CAGR) of 36.3%. This significant growth potential has ignited global investment interest in the anti-cancer field and drawn attention to a key Chinese pioneer in BNCT: Pengbo (Hainan) Boron Neutron Hospital.

From a "Crown Jewel" to a Vast Market: Why is BNCT the New Favorite in Cancer Treatment? Boron Neutron Capture Therapy (BNCT) is often hailed as the "crown jewel" of modern radiotherapy. Its core mechanism involves administering a targeted drug containing the boron-10 isotope to the patient, causing a high concentration of boron to accumulate specifically in cancer cells. Subsequently, a low-energy thermal neutron beam is applied, triggering a nuclear fission reaction within the cells. The released alpha particles and lithium nuclei precisely destroy the cancer cells within a range roughly the size of a single cell, causing minimal damage to surrounding healthy tissue. This "cellular scalpel" level of precision, combined with advantages such as a single treatment session lasting about 40 minutes, repeatability, and minimal side effects, positions BNCT as the globally recognized next-generation radiotherapy technology with the greatest potential.

Global Market Accelerates Expansion: Over Six-Fold Growth in Six Years According to the YH Research report, the global BNCT market is experiencing explosive growth: - Market Size in 2026: $528 million - Market Size in 2032: $3.39 billion - Compound Annual Growth Rate (CAGR): 36.3% Geographically, the Asia-Pacific region is currently the largest BNCT market, holding about 61% of the global share, followed by North America and Europe with approximately 24% and 13%, respectively. In terms of product structure, BNCT equipment constitutes the majority, accounting for 60% of the market. Regarding indications, head and neck cancers represent about 55% of applications. Notably, key participants in the global BNCT industry chain include Neutron Therapeutics, Sumitomo Heavy Industries, International Particle Therapy Inc. (IPT), RaySearch, Zhongbor Medical, TAE Life Sciences, and Stella Pharma, among others. The top five global manufacturers collectively account for about 58% of total revenue. Major entities like Google and interests associated with Donald Trump have also entered the BNCT arena. Google Research has been investing in TAE since 2015, incorporating AI for optimization. In December 2025, TAE Technologies announced a merger with Trump Media & Technology Group (DJT). TAE Life Sciences, a primary subsidiary of TAE Technologies, focuses on BNCT equipment development.

China's BNCT Era Begins: Pengbo Hospital Takes the Lead In June 2022, Pengbo (Hainan), under CH BIOTECH SER (08037), signed an official agreement with an overseas manufacturer, securing exclusive rights to introduce the BNCT treatment system "NeuCure" and the boron drug "Steboronine" into the Chinese market. By March 2026, Pengbo (Hainan) Boron Neutron Hospital began formally accepting patients, becoming the first medical institution in mainland China approved for BNCT clinical application. This milestone marks the official entry of this leading global technology into clinical practice in China, filling a significant gap in the country's high-end cancer treatment sector.

The Trajectory of BNCT in China Following the completion of the overseas partnership agreement in June 2022, the project center's main structure was finished by the end of 2023. After equipment installation and rigorous testing, the NeuCure® system achieved its first neutron beam output on November 20, 2025, transitioning from infrastructure development to clinical preparation. Trial operations commenced in February 2026, leading to its status as the first approved BNCT clinical application site in mainland China. The hospital's treatment window officially opened in March 2026.

The Future: A Pioneer on a Trillion-Dollar Track BNCT is rapidly advancing along a path of precision, accessibility, and industrialization. Driven by both the pioneering policies of China's Boao and the surging global market demand, Pengbo (Hainan) Boron Neutron Hospital, as the nation's first approved BNCT treatment center, has secured a leading position in this new anti-cancer frontier. The overseas BNCT system it introduced, being the world's only approved drug-device combination, is leading China's BNCT industry through a pivotal golden turning point—from "technology introduction" to "accelerated commercialization"—leveraging its robust clinical data (with over a thousand real-world treatment cases globally) and a replicable, mature business model.